ACIT 1

Drug Profile

ACIT 1

Alternative Names: ACIT-1; ACIT-1 cancer vaccine

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Cancer Vaccines Limited
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cancer; Pancreatic cancer

Most Recent Events

  • 01 Apr 2017 Phase-I/II clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom (Intradermal)
  • 01 Apr 2017 Phase-I/II clinical trials in Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom (Intradermal)
  • 31 Mar 2017 Cancer Vaccines plans a phase I/II trial for Pancreatic cancer and other cancers (Late-stage disease, Second-line therapy or greater) in United Kingdom (NCT03096093)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top